Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Sep 7, 2016 (10 years ago)

Varithena (polidocanol injectable foam)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Defective Delivery System: Incorrect type of syringe found in commercially distributed administration pack

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Varithena (polidocanol injectable foam) Administration Pack For Use With Varithena, Rx only, Distributed by Biocompatibles, Inc. Oxford, CT 06478, NDC 60635-123-01

Affected NDC 60635-0123-01

Compare with the code on your package — it is the most precise check available.

Drug: Polidocanol

Recalling firm
Biocompatibles U.K., Ltd.
NDC code
60635-123-01
Origin
N/A, United Kingdom
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0001-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Polidocanol recalls

See all
Class III · Low risk

Varithena (polidocanol injectable foam)

Defective Delivery System: incorrect silicone oil-free NormJect 10 mL Luer Lock Solo syringes packaged in the pack, instead of the required silicone oil-free NormJect 10 mL Luer Solo syringes (luer slip connection).

Terminated Packaging defect Biocompatibles UK, Ltd. D-0113-2025
Class II · Moderate risk

Polidocanol 50mg/Ml

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0231-2023
Class II · Moderate risk

Polidocanol 5% Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1625-2015

Other packaging defect recalls from 2016

All packaging defect recalls
Class III · Low risk

Azelastine Hydrochloride Nasal Solution

Defective Delivery System: out of specification result for droplet size distribution at the d90 measurement testing during the 6 month time point..

Terminated Packaging defect Roxane Laboratories, Inc. NDC 0054-0293-99 D-0448-2017
Class I · High risk

GlucaGen HypoKit

Defective delivery system: detached needles on the syringe in the kit.

Terminated Packaging defect Novo Nordisk Inc NDC 0169-7065-15 D-0217-2017
Class II · Moderate risk

Transderm Scop

Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.

Terminated Packaging defect Sandoz Inc D-0133-2017